COX-2s drive OTCs at CVS
This article was originally published in The Tan Sheet
Executive Summary
Sales of OTC NSAIDs and generic products are increasing at the pharmacy chain as a result of safety concerns surrounding COX-2s, CEO Thomas Ryan said during an earnings call Feb. 2. FDA's Arthritis Drug and Drug Safety & Risk Management advisory committees will evaluate COX-2 and NSAID safety during a meeting Feb. 16-18 (1"The Tan Sheet" Jan. 17, 2005, p. 9)...
You may also be interested in...
FDA Advisors Will Give Gut Reaction On COX-2s In Three-Day Meeting
FDA's Arthritis Drugs and Drug Safety & Risk Management advisory committees will discuss the gastrointestinal safety and cardiovascular side effects of COX-2 inhibitors at their February joint meeting
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.